Carmen Calfa

Medicine & Life Sciences

1. Trastuzumab 100%
2. Breast Neoplasms 93%
3. Registries 64%
4. Antibodies 48%
5. Non-Small Cell Lung Carcinoma 48%
6. Immunity 44%
7. palbociclib 43%
8. T-Cell Prolymphocytic Leukemia 42%
9. Lapatinib 38%
10. pembrolizumab 38%
11. Cetuximab 33%
12. Cancer Survivors 29%
13. Ovarian Neoplasms 28%
14. Drug Therapy 26%
15. Survival 26%
16. Tumor Burden 25%
17. Endostatins 25%
18. Neoplasms 24%
19. Life Style 22%
20. T-Cell Lymphoma 20%
21. Proteins 19%
22. Progression-Free Survival 19%
23. Ligands 19%
24. Mutation 18%
25. Therapeutics 17%
26. Eye 16%
27. Recurrence 15%
28. T-Lymphocytes 15%
29. Angiogenic Proteins 13%
30. Antibody Formation 12%
31. Disease-Free Survival 11%
32. Biopsy 10%
33. Clinical Trials 10%
34. Immunoglobulin G 10%
35. Proxy 8%
36. Rare Diseases 8%
37. Weights and Measures 8%
38. Serum 8%
39. Overweight 7%
40. Ocular Vision 7%
41. Angiogenesis Inhibitors 7%
42. Flow Cytometry 6%
43. Safety 6%
44. Bone Marrow 6%
45. Tetanus Toxin 6%
46. Combination Drug Therapy 6%
47. Growth 6%
48. Natural Killer Cells 6%